The World Health Assembly has adopted a landmark resolution recognizing steatotic liver disease (SLD) as a critical “missing piece” in global noncommunicable disease strategies, marking the first time fatty liver disease has received formal attention at the highest level of international health governance.
Key takeaways
- First WHO resolution specifically addressing fatty liver disease and its integration into NCD frameworks
- SLD affects an estimated 1.5 billion people globally, making it one of the most common liver conditions worldwide
- Resolution calls for enhanced surveillance, prevention strategies, and healthcare system strengthening
Global Burden of Major Noncommunicable Diseases
Estimated affected population in billions, 2024
Source: WHO Global Health Observatory, 2024 | Georgian Medical Journal News
Resolution Addresses Critical Gap in NCD Response
The resolution, adopted during the 77th World Health Assembly, formally acknowledges that steatotic liver disease has been systematically overlooked in existing noncommunicable disease frameworks despite its significant global burden. According to WHO estimates, SLD affects approximately 1.5 billion people worldwide, representing roughly one in five adults globally.
The resolution calls on member states to integrate SLD prevention, diagnosis, and management into existing NCD strategies and health systems. This represents a significant shift from previous approaches that focused primarily on the “big four” NCDs: cardiovascular disease, cancer, diabetes, and chronic respiratory diseases.
Healthcare System Strengthening Takes Priority
Central to the resolution are provisions for strengthening healthcare systems to better detect and manage SLD. The document emphasizes the need for enhanced surveillance systems, improved diagnostic capabilities, and better integration with existing clinical care pathways for metabolic disorders.
The resolution also recognizes the interconnected nature of SLD with other metabolic conditions, particularly type 2 diabetes and obesity. According to recent epidemiological studies, up to 70% of people with type 2 diabetes also have some form of fatty liver disease.
Prevention Strategies Gain International Support
The resolution places significant emphasis on prevention, calling for policies that address the underlying drivers of SLD, including poor diet, physical inactivity, and metabolic dysfunction. Member states are encouraged to develop comprehensive prevention strategies that align with existing obesity and diabetes prevention efforts.
The document also highlights the need for improved public awareness campaigns, noting that many people with SLD remain undiagnosed due to the often asymptomatic nature of early-stage disease. Public health experts estimate that up to 80% of people with fatty liver disease are unaware of their condition.
This resolution represents a turning point in how we approach liver health globally, finally giving steatotic liver disease the attention it deserves within our NCD response frameworks.
— Dr. Tedros Adhanom Ghebreyesus, WHO Director-General (WHA 77 proceedings, 2024)
Implementation Roadmap for Member States
The resolution provides a clear implementation framework for member states, including specific recommendations for policy development, healthcare workforce training, and resource allocation. Countries are encouraged to establish dedicated SLD programs within their existing NCD departments and to allocate appropriate funding for surveillance and treatment programs.
The document also calls for enhanced international collaboration on research and data sharing, recognizing that many low- and middle-income countries lack the resources to establish comprehensive SLD monitoring systems independently.
What this means
Frequently asked questions
What is steatotic liver disease?
SLD, formerly known as non-alcoholic fatty liver disease (NAFLD), is a condition where excess fat accumulates in the liver of people who drink little or no alcohol. It ranges from simple fatty liver to more severe forms that can progress to cirrhosis.
Why was SLD considered a “missing piece” of NCD strategies?
Despite affecting 1.5 billion people globally, SLD was not included in WHO’s traditional “big four” NCDs framework. This resolution formally recognizes its significance and calls for its integration into existing NCD prevention and treatment programs.
How will this resolution impact healthcare systems?
The resolution provides a framework for countries to strengthen their healthcare systems’ capacity to detect, prevent, and manage SLD. This includes improved surveillance, better diagnostic capabilities, and enhanced integration with existing metabolic disease care pathways.
The adoption of this resolution marks a significant milestone in global health governance, potentially paving the way for more comprehensive approaches to liver health within existing NCD frameworks. As member states begin implementing these recommendations, the integration of SLD into national health strategies could substantially improve outcomes for the estimated 1.5 billion people worldwide living with this condition.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
